4.7 Article

Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy

Journal

STEM CELL RESEARCH & THERAPY
Volume 12, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13287-020-02099-3

Keywords

Dental pulp stem cells; Duchenne muscular dystrophy; Anti-inflammatory therapy

Funding

  1. JCR Pharmaceuticals Co., Ltd.
  2. Health Sciences Research Grants for Research on Human Genome and Gene Therapy from the Ministry of Health, Labor and Welfare of Japan [21A-3]
  3. Ministry of Education, Culture, Sports, Science and Technology [22390284, 22-40134]
  4. Nippon Medical School
  5. Grants-in-Aid for Scientific Research [22390284] Funding Source: KAKEN

Ask authors/readers for more resources

This study demonstrates the potential therapeutic benefits of systemic treatment with dental pulp stem cells (DPSCs) in Duchenne muscular dystrophy (DMD). DPSC-treated animal models showed improved muscle function and locomotor activity with downregulated inflammation. Interestingly, long-term follow-up also revealed maintenance of running capability and stabilized cardiac function after DPSC treatment.
BackgroundDuchenne muscular dystrophy (DMD) is an inherited progressive disorder that causes skeletal and cardiac muscle deterioration with chronic inflammation. Dental pulp stem cells (DPSCs) are attractive candidates for cell-based strategies for DMD because of their immunosuppressive properties. Therefore, we hypothesized that systemic treatment with DPSCs might show therapeutic benefits as an anti-inflammatory therapy.MethodsTo investigate the potential benefits of DPSC transplantation for DMD, we examined disease progression in a DMD animal model, mdx mice, by comparing them with different systemic treatment conditions. The DPSC-treated model, a canine X-linked muscular dystrophy model in Japan (CXMDJ), which has a severe phenotype similar to that of DMD patients, also underwent comprehensive analysis, including histopathological findings, muscle function, and locomotor activity.ResultsWe demonstrated a therapeutic strategy for long-term functional recovery in DMD using repeated DPSC administration. DPSC-treated mdx mice and CXMDJ showed no serious adverse events. MRI findings and muscle histology suggested that DPSC treatment downregulated severe inflammation in DMD muscles and demonstrated a milder phenotype after DPSC treatment. DPSC-treated models showed increased recovery in grip-hand strength and improved tetanic force and home cage activity. Interestingly, maintenance of long-term running capability and stabilized cardiac function was also observed in 1-year-old DPSC-treated CXMDJ.ConclusionsWe developed a novel strategy for the safe and effective transplantation of DPSCs for DMD recovery, which included repeated systemic injection to regulate inflammation at a young age. This is the first report on the efficacy of a systemic DPSC treatment, from which we can propose that DPSCs may play an important role in delaying the DMD disease phenotype.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available